Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
56
THNR Quote, Financials, Valuation and Earnings
Last price:
$25.04
Seasonality move
:
-5.53%
Day range:
$24.97 - $25.41
52-week range:
$18.56 - $27.28
Dividend yield:
1.63%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
244
Avg. volume:
4.1K
1-year change:
9.46%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | -- | -- | -- | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
-- | -- | -- | -- | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | -- | -- | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
|
RSPH
Invesco S&P 500 Eql Wght Health Care ETF
|
-- | -- | -- | -- | -- |
|
XBI
State Street SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
$25.41 | -- | -- | -- | $0.41 | 1.63% | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
$204.65 | -- | -- | -- | $1.17 | 0% | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
$35.15 | -- | -- | -- | $0.35 | 0.99% | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
$107.74 | -- | -- | -- | $0.25 | 0.95% | -- |
|
RSPH
Invesco S&P 500 Eql Wght Health Care ETF
|
$32.74 | -- | -- | -- | $0.05 | 0.68% | -- |
|
XBI
State Street SPDR S&P Biotech ETF
|
$126.42 | -- | -- | -- | $0.41 | 0.35% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | 0.745 | -- | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
-- | 0.317 | -- | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | 0.901 | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -0.062 | -- | -- |
|
RSPH
Invesco S&P 500 Eql Wght Health Care ETF
|
-- | 0.232 | -- | -- |
|
XBI
State Street SPDR S&P Biotech ETF
|
-- | 0.808 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | -- | -- | -- | -- | -- |
|
FBT
First Trust NYSE Arca Biotechnology Index Fund
|
-- | -- | -- | -- | -- | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | -- | -- | -- | -- | -- |
|
PJP
Invesco Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
|
RSPH
Invesco S&P 500 Eql Wght Health Care ETF
|
-- | -- | -- | -- | -- | -- |
|
XBI
State Street SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- | -- |
Amplify Weight Loss Drug & Treatment ETF vs. Competitors
-
Which has Higher Returns THNR or FBT?
First Trust NYSE Arca Biotechnology Index Fund has a net margin of -- compared to Amplify Weight Loss Drug & Treatment ETF's net margin of --. Amplify Weight Loss Drug & Treatment ETF's return on equity of -- beat First Trust NYSE Arca Biotechnology Index Fund's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- FBTFirst Trust NYSE Arca Biotechnology Index Fund-- -- -- -
What do Analysts Say About THNR or FBT?
Amplify Weight Loss Drug & Treatment ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust NYSE Arca Biotechnology Index Fund has an analysts' consensus of -- which suggests that it could fall by --. Given that Amplify Weight Loss Drug & Treatment ETF has higher upside potential than First Trust NYSE Arca Biotechnology Index Fund, analysts believe Amplify Weight Loss Drug & Treatment ETF is more attractive than First Trust NYSE Arca Biotechnology Index Fund.
Company Buy Ratings Hold Ratings Sell Ratings THNRAmplify Weight Loss Drug & Treatment ETF0 0 0 FBTFirst Trust NYSE Arca Biotechnology Index Fund0 0 0 -
Is THNR or FBT More Risky?
Amplify Weight Loss Drug & Treatment ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison First Trust NYSE Arca Biotechnology Index Fund has a beta of 0.743, suggesting its less volatile than the S&P 500 by 25.703%.
-
Which is a Better Dividend Stock THNR or FBT?
Amplify Weight Loss Drug & Treatment ETF has a quarterly dividend of $0.41 per share corresponding to a yield of 1.63%. First Trust NYSE Arca Biotechnology Index Fund offers a yield of 0% to investors and pays a quarterly dividend of $1.17 per share. Amplify Weight Loss Drug & Treatment ETF pays -- of its earnings as a dividend. First Trust NYSE Arca Biotechnology Index Fund pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios THNR or FBT?
Amplify Weight Loss Drug & Treatment ETF quarterly revenues are --, which are smaller than First Trust NYSE Arca Biotechnology Index Fund quarterly revenues of --. Amplify Weight Loss Drug & Treatment ETF's net income of -- is lower than First Trust NYSE Arca Biotechnology Index Fund's net income of --. Notably, Amplify Weight Loss Drug & Treatment ETF's price-to-earnings ratio is -- while First Trust NYSE Arca Biotechnology Index Fund's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amplify Weight Loss Drug & Treatment ETF is -- versus -- for First Trust NYSE Arca Biotechnology Index Fund. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- -- FBTFirst Trust NYSE Arca Biotechnology Index Fund-- -- -- --
-
Which has Higher Returns THNR or HTEC?
ROBO Global Healthcare Technology & Innovation ETF has a net margin of -- compared to Amplify Weight Loss Drug & Treatment ETF's net margin of --. Amplify Weight Loss Drug & Treatment ETF's return on equity of -- beat ROBO Global Healthcare Technology & Innovation ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- -
What do Analysts Say About THNR or HTEC?
Amplify Weight Loss Drug & Treatment ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand ROBO Global Healthcare Technology & Innovation ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Amplify Weight Loss Drug & Treatment ETF has higher upside potential than ROBO Global Healthcare Technology & Innovation ETF, analysts believe Amplify Weight Loss Drug & Treatment ETF is more attractive than ROBO Global Healthcare Technology & Innovation ETF.
Company Buy Ratings Hold Ratings Sell Ratings THNRAmplify Weight Loss Drug & Treatment ETF0 0 0 HTECROBO Global Healthcare Technology & Innovation ETF0 0 0 -
Is THNR or HTEC More Risky?
Amplify Weight Loss Drug & Treatment ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ROBO Global Healthcare Technology & Innovation ETF has a beta of 1.227, suggesting its more volatile than the S&P 500 by 22.745%.
-
Which is a Better Dividend Stock THNR or HTEC?
Amplify Weight Loss Drug & Treatment ETF has a quarterly dividend of $0.41 per share corresponding to a yield of 1.63%. ROBO Global Healthcare Technology & Innovation ETF offers a yield of 0.99% to investors and pays a quarterly dividend of $0.35 per share. Amplify Weight Loss Drug & Treatment ETF pays -- of its earnings as a dividend. ROBO Global Healthcare Technology & Innovation ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios THNR or HTEC?
Amplify Weight Loss Drug & Treatment ETF quarterly revenues are --, which are smaller than ROBO Global Healthcare Technology & Innovation ETF quarterly revenues of --. Amplify Weight Loss Drug & Treatment ETF's net income of -- is lower than ROBO Global Healthcare Technology & Innovation ETF's net income of --. Notably, Amplify Weight Loss Drug & Treatment ETF's price-to-earnings ratio is -- while ROBO Global Healthcare Technology & Innovation ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amplify Weight Loss Drug & Treatment ETF is -- versus -- for ROBO Global Healthcare Technology & Innovation ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- -- HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- --
-
Which has Higher Returns THNR or PJP?
Invesco Pharmaceuticals ETF has a net margin of -- compared to Amplify Weight Loss Drug & Treatment ETF's net margin of --. Amplify Weight Loss Drug & Treatment ETF's return on equity of -- beat Invesco Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- PJPInvesco Pharmaceuticals ETF-- -- -- -
What do Analysts Say About THNR or PJP?
Amplify Weight Loss Drug & Treatment ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Amplify Weight Loss Drug & Treatment ETF has higher upside potential than Invesco Pharmaceuticals ETF, analysts believe Amplify Weight Loss Drug & Treatment ETF is more attractive than Invesco Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings THNRAmplify Weight Loss Drug & Treatment ETF0 0 0 PJPInvesco Pharmaceuticals ETF0 0 0 -
Is THNR or PJP More Risky?
Amplify Weight Loss Drug & Treatment ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Invesco Pharmaceuticals ETF has a beta of 0.511, suggesting its less volatile than the S&P 500 by 48.861%.
-
Which is a Better Dividend Stock THNR or PJP?
Amplify Weight Loss Drug & Treatment ETF has a quarterly dividend of $0.41 per share corresponding to a yield of 1.63%. Invesco Pharmaceuticals ETF offers a yield of 0.95% to investors and pays a quarterly dividend of $0.25 per share. Amplify Weight Loss Drug & Treatment ETF pays -- of its earnings as a dividend. Invesco Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios THNR or PJP?
Amplify Weight Loss Drug & Treatment ETF quarterly revenues are --, which are smaller than Invesco Pharmaceuticals ETF quarterly revenues of --. Amplify Weight Loss Drug & Treatment ETF's net income of -- is lower than Invesco Pharmaceuticals ETF's net income of --. Notably, Amplify Weight Loss Drug & Treatment ETF's price-to-earnings ratio is -- while Invesco Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amplify Weight Loss Drug & Treatment ETF is -- versus -- for Invesco Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- -- PJPInvesco Pharmaceuticals ETF-- -- -- --
-
Which has Higher Returns THNR or RSPH?
Invesco S&P 500 Eql Wght Health Care ETF has a net margin of -- compared to Amplify Weight Loss Drug & Treatment ETF's net margin of --. Amplify Weight Loss Drug & Treatment ETF's return on equity of -- beat Invesco S&P 500 Eql Wght Health Care ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- RSPHInvesco S&P 500 Eql Wght Health Care ETF-- -- -- -
What do Analysts Say About THNR or RSPH?
Amplify Weight Loss Drug & Treatment ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco S&P 500 Eql Wght Health Care ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Amplify Weight Loss Drug & Treatment ETF has higher upside potential than Invesco S&P 500 Eql Wght Health Care ETF, analysts believe Amplify Weight Loss Drug & Treatment ETF is more attractive than Invesco S&P 500 Eql Wght Health Care ETF.
Company Buy Ratings Hold Ratings Sell Ratings THNRAmplify Weight Loss Drug & Treatment ETF0 0 0 RSPHInvesco S&P 500 Eql Wght Health Care ETF0 0 0 -
Is THNR or RSPH More Risky?
Amplify Weight Loss Drug & Treatment ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Invesco S&P 500 Eql Wght Health Care ETF has a beta of 0.931, suggesting its less volatile than the S&P 500 by 6.9%.
-
Which is a Better Dividend Stock THNR or RSPH?
Amplify Weight Loss Drug & Treatment ETF has a quarterly dividend of $0.41 per share corresponding to a yield of 1.63%. Invesco S&P 500 Eql Wght Health Care ETF offers a yield of 0.68% to investors and pays a quarterly dividend of $0.05 per share. Amplify Weight Loss Drug & Treatment ETF pays -- of its earnings as a dividend. Invesco S&P 500 Eql Wght Health Care ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios THNR or RSPH?
Amplify Weight Loss Drug & Treatment ETF quarterly revenues are --, which are smaller than Invesco S&P 500 Eql Wght Health Care ETF quarterly revenues of --. Amplify Weight Loss Drug & Treatment ETF's net income of -- is lower than Invesco S&P 500 Eql Wght Health Care ETF's net income of --. Notably, Amplify Weight Loss Drug & Treatment ETF's price-to-earnings ratio is -- while Invesco S&P 500 Eql Wght Health Care ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amplify Weight Loss Drug & Treatment ETF is -- versus -- for Invesco S&P 500 Eql Wght Health Care ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- -- RSPHInvesco S&P 500 Eql Wght Health Care ETF-- -- -- --
-
Which has Higher Returns THNR or XBI?
State Street SPDR S&P Biotech ETF has a net margin of -- compared to Amplify Weight Loss Drug & Treatment ETF's net margin of --. Amplify Weight Loss Drug & Treatment ETF's return on equity of -- beat State Street SPDR S&P Biotech ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- XBIState Street SPDR S&P Biotech ETF-- -- -- -
What do Analysts Say About THNR or XBI?
Amplify Weight Loss Drug & Treatment ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand State Street SPDR S&P Biotech ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Amplify Weight Loss Drug & Treatment ETF has higher upside potential than State Street SPDR S&P Biotech ETF, analysts believe Amplify Weight Loss Drug & Treatment ETF is more attractive than State Street SPDR S&P Biotech ETF.
Company Buy Ratings Hold Ratings Sell Ratings THNRAmplify Weight Loss Drug & Treatment ETF0 0 0 XBIState Street SPDR S&P Biotech ETF0 0 0 -
Is THNR or XBI More Risky?
Amplify Weight Loss Drug & Treatment ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison State Street SPDR S&P Biotech ETF has a beta of 0.951, suggesting its less volatile than the S&P 500 by 4.899%.
-
Which is a Better Dividend Stock THNR or XBI?
Amplify Weight Loss Drug & Treatment ETF has a quarterly dividend of $0.41 per share corresponding to a yield of 1.63%. State Street SPDR S&P Biotech ETF offers a yield of 0.35% to investors and pays a quarterly dividend of $0.41 per share. Amplify Weight Loss Drug & Treatment ETF pays -- of its earnings as a dividend. State Street SPDR S&P Biotech ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios THNR or XBI?
Amplify Weight Loss Drug & Treatment ETF quarterly revenues are --, which are smaller than State Street SPDR S&P Biotech ETF quarterly revenues of --. Amplify Weight Loss Drug & Treatment ETF's net income of -- is lower than State Street SPDR S&P Biotech ETF's net income of --. Notably, Amplify Weight Loss Drug & Treatment ETF's price-to-earnings ratio is -- while State Street SPDR S&P Biotech ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amplify Weight Loss Drug & Treatment ETF is -- versus -- for State Street SPDR S&P Biotech ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- -- XBIState Street SPDR S&P Biotech ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
42
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
93
NBTX alert for Mar 5
Nanobiotix SA [NBTX] is down 7.15% over the past day.
Sell
45
MRNA alert for Mar 5
Moderna, Inc. [MRNA] is down 6.83% over the past day.
Buy
77
SSRM alert for Mar 5
SSR Mining, Inc. [SSRM] is down 6.13% over the past day.
